Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5412-5426

  Stevenson, Leanne ^a   Allen, Wendy L ^a   Turkington, Richard ^a   Jithesh, Puthen V ^a   Proutski, Irina ^a   Stewart, Gail ^a   Lenz, Heinz Josef ^b   Van Schaeybroeck, Sandra ^a   Longley, Daniel B ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; FLICE INHIBITORY PROTEIN L; FLUOROURACIL; GALANIN; GALANIN RECEPTOR 1; INSULIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG TARGETING; ENZYME INDUCTION; FOCAL ADHESION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER BIOPSY; LIVER METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GALANIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; RECEPTOR, GALANIN, TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84866932861     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1780     Document Type: Article

References (47)

1. Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 2001;12:639-46. (Pubitemid 32844203)
2. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47. (Pubitemid 30036347)
3. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92. (Pubitemid 40227997)
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8. (Pubitemid 37328853)
5. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006;1766:184-96.
6. Allen WL, Coyle VM, Jithesh PV, Proutski I, Stevenson L, Fenning C, et al. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res 2008;14: 6647-55.
7. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835- 48.
8. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11:498-512. (Pubitemid 46856907)
9. Bhattacharya B, Miura T, Brandenberger R, Mejido J, Luo Y, Yang AX, et al. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood 2004;103:2956-64. (Pubitemid 38451667)
10. Zeng X, Miura T, Luo Y, Bhattacharya B, Condie B, Chen J, et al. Properties of pluripotent human embryonic stem cells BG01 and BG02. Stem Cells 2004;22:292-312. (Pubitemid 38736614)
11. Tarasov KV, Tarasova YS, Crider DG, Anisimov SV, Wobus AM, Boheler KR. Galanin and galanin receptors in embryonic stem cells: accidental or essential? Neuropeptides 2002;36:239-45. (Pubitemid 35192184)
12. Kimber SJ, Sneddon SF, Bloor DJ, El-Bareg AM, Hawkhead JA, Metcalfe AD, et al. Expression of genes involved in early cell fate decisions in human embryos and their regulation by growth factors. Reproduction 2008;135:635-47. (Pubitemid 351676448)
13. Louridas M, Letourneau S, Lautatzis ME, Vrontakis M. Galanin is highly expressed in bone marrow mesenchymal stem cells and facilitates migration of cells both in vitro and in vivo. Biochem Biophys Res Commun 2009;390:867-71.
14. Anisimov SV, Tarasov KV, Tweedie D, Stern MD, Wobus AM, Boheler KR. SAGE identification of gene transcripts with profiles unique to pluripotent mouse R1 embryonic stem cells. Genomics 2002;79: 169- 76.
15. Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, et al. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther 2012;11:119-31.
16. Boyer J, McLean E, Aroori S, Wilson P, McCulla A, Carey P, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10:2158-67. (Pubitemid 38375578)
17. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006;25:838-48. (Pubitemid 43237702)
18. Stevenson L, Allen WL, Proutski I, Stewart G, Johnston L, McCloskey K, et al. Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. PLoS One 2011;6:e20276.
19. http://www.ebi.ac.uk/arrayexpress/
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545- 50.
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
22. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM, et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007;67:5754-62. (Pubitemid 46985008)
23. http://www.oncomine.org
24. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, et al. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006;7:R19.
25. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007;121:2005-12.
26. http://gibk21.bio.kyutech.ac.jp/PrognoScan/index.html
27. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138:958-68.
28. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
29. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004;306:636-40.
30. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115:177-207. (Pubitemid 47042915)
31. Tjomsland V, El-Salhy M. Effects of single, double or triple combinations of octreotide, galanin, and serotonin on a human pancreatic cancer cell line. Histol Histopathol 2005;20:537-41. (Pubitemid 40468274)
32. Seufferlein T, Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 1996;56:5758-64. (Pubitemid 26422185)
33. Hammond PJ, Smith DM, Akinsanya KO, Mufti WA, Wynick D, Bloom SR. Signaling pathways mediating secretory and mitogenic responses to galanin and pituitary adenylate cyclase-activating polypeptide in the 235-1 clonal rat lactotroph cell line. J Neuroendocrinol 1996;8:457-64. (Pubitemid 26288982)
34. Kim KY, Kee MK, Chong SA, Nam MJ. Galanin is upregulated in colon adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2007;16:2373-8.
35. Nakao M, Kawauchi S, Furuya T, Uchiyama T, Adachi J, Okada T, et al. Identification of DNA copy number aberrations associated with metastases of colorectal cancer using array CGH profiles. Cancer Genet Cytogenet 2009;188:70-6.
36. Vendrell E, Ribas M, Valls J, Sole X, Grau M, Moreno V, et al. Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients. Int J Oncol 2007;30:1099-107.
37. Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, et al. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res 2008;14:7604-13.
38. Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch 2002;440:187-94. (Pubitemid 34169857)
39. Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 2007;26:5762-71. (Pubitemid 47312818)
40. Skotheim RI, Lind GE, Monni O, Nesland JM, Abeler VM, Fossa SD, et al. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 2005;65:5588-98. (Pubitemid 40911159)
41. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 2005;5:275- 84.
42. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
43. Johnston PG. Stage II colorectal cancer: to treat or not to treat. Oncologist 2005;10:332-4. (Pubitemid 40647251)
44. Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjanen S, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer 2009;40:91- 7.
45. Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer - a study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153-62.
46. Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 2011;29:4620-6.
47. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, et al. Prognostic signi ficance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010;16:3442-51.